Equities researchers at Roth Capital assumed coverage on shares of Matinas BioPharma (NYSEAMERICAN:MTNB) in a research report issued on Monday. The brokerage set a “buy” rating on the stock.

Separately, Maxim Group boosted their price target on Matinas BioPharma from $2.00 to $5.00 and gave the stock a “buy” rating in a research report on Monday, November 12th.

Shares of MTNB traded up $0.05 during mid-day trading on Monday, reaching $1.08. The company had a trading volume of 4,900 shares, compared to its average volume of 1,055,389. Matinas BioPharma has a 52 week low of $0.32 and a 52 week high of $1.48.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings results on Monday, November 12th. The company reported ($0.03) EPS for the quarter.

A number of institutional investors and hedge funds have recently made changes to their positions in MTNB. Private Advisor Group LLC boosted its holdings in shares of Matinas BioPharma by 100.4% during the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after purchasing an additional 24,978 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Matinas BioPharma in the 4th quarter valued at about $39,000. Renaissance Technologies LLC lifted its holdings in shares of Matinas BioPharma by 325.6% in the 3rd quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $124,000 after acquiring an additional 103,200 shares during the last quarter. K.J. Harrison & Partners Inc bought a new position in shares of Matinas BioPharma in the 3rd quarter valued at about $150,000. Finally, BlackRock Inc. lifted its holdings in shares of Matinas BioPharma by 147.1% in the 4th quarter. BlackRock Inc. now owns 290,589 shares of the company’s stock valued at $173,000 after acquiring an additional 173,005 shares during the last quarter.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Featured Article: Book Value Per Share – BVPS

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.